Abstract
The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb/IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb/IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.
| Original language | English |
|---|---|
| Pages (from-to) | 703-709 |
| Number of pages | 7 |
| Journal | Mini-Reviews in Medicinal Chemistry |
| Volume | 4 |
| Issue number | 7 |
| Publication status | Published - Sep 2004 |
Keywords
- Acute coronary syndromes
- Atherosclerotic plaque
- Glycoprotein IIb/IIIa receptor
- Percutaneous coronary intervention
- Platelet aggregation inhibitors
ASJC Scopus subject areas
- Chemistry(all)
- Medicine (miscellaneous)
- Pharmacology